GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.
An article from
GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.
Published July 10, 2026
GSK licensed most rights to an antibody-drug conjugate called ris-rez from Hansoh Pharma in 2023.
Getty Images
GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company moves to end its collaboration…
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
An experimental antibody treatment that binds to a protein known as PCDH7 shrank tumors in preclinical models of non-small cell…
Akeso's ivonescimab reduces death risk by 34% in phase three lung cancer trial, the first Chinese drug selected for ASCO's…
At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway…
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important…
